Service Line Director: Dr. Lindsay Standeven, M.D.
Nursing Director(s): Kelly Caslin, DNP, RN, NEA-BC
Admissions Coordinator: Tracey Baker

The Johns Hopkins Reproductive Mental Health Center (RMHC) in the department of Psychiatry and Behavioral Services is pleased to offer the first-ever U.S. Food and Drug Administration (FDA) approved medication for the treatment of postpartum depression (PPD), ZULRESSO^® (brexanolone). Brexanolone is administered through intravenous (IV) infusion over a total of 60 hours (2.5 days).

Johns Hopkins uniquely offers Brexanolone on our inpatient psychiatric floors, which affords patients the opportunity to receive the treatment and participate in our inpatient psychiatric services.

Interested persons may qualify if you are:

• aged 18-50
• Presenting less than or equal to 6 months postpartum, with a diagnosis of major depression.
• Onset of depression symptoms between 26 weeks’ of pregnancy and 6 weeks postpartum, documented by a physician and/or validated by a screening tool such as the Edinburgh Postnatal Depression Scale (EPDS)

Patients with a history of bipolar disorders, psychotic disorders, and active substance use disorders are not eligible. Patients with symptoms of depression starting prior to 26 weeks’ gestation OR after 6 weeks postpartum are not eligible for this treatment Patients may have other co-morbid psychiatric disorders, including anxiety disorders, OCD and PTSD.

Interested patients may contact our Intake Coordinator, Tracy Baker at [email protected], 410-955-5104.

Interested patients may need a full psychiatric evaluation to verify eligibility for treatment.

Questions about clinical eligibility and treatment can be directed to Dr. Lindsay R. Standeven, [email protected]